Artiva Biotherapeutics (ARTV) 2025 Conference June 04, 2025 09:20 AM ET Speaker0 Good morning, everyone. Thank you for attending Jefferies Healthcare Conference. My name is Kelly Xu, one of the equity analysts here on the biotech team. We are very pleased to have Doctor. Fred Aslan, CEO of Ativa Biotherapeutics join us today. Welcome, Fred. Speaker1 Thank you, Kelly. Speaker0 And maybe let's first start with a big picture question. Many cell therapies in the autoimmune space originated from oncology and Ati ...

SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. EDT. Members of the Artiva management team will also be available to participate in investo ...

Core Insights - Artiva Biotherapeutics announced promising long-term Phase 1/2 data for AlloNK® in combination with rituximab for patients with relapsed/refractory B-cell non-Hodgkin lymphoma, showing a 64% complete response rate and a median duration of response of at least 19.4 months [1][2][3] Group 1: Clinical Data - AlloNK + rituximab demonstrated a 64% complete response rate (9 out of 14 patients) in heavily pretreated patients who were naïve to prior CAR-T cell therapy [1][3] - The median duration of response is at least 19.4 months, indicating durability comparable to approved auto-CAR-T therapies [1][3] - The safety profile of AlloNK + rituximab was well-tolerated among 45 patients, with no reports of immune effector cell associated neurotoxicity syndrome (ICANS) or graft-versus-host disease [7] Group 2: Comparison with CAR-T Therapies - The complete response rate of AlloNK + rituximab is comparable to outcomes from approved auto-CAR-T therapies, which reported 58% for Yescarta, 53% for Breyanzi, and 40% for Kymriah [3] - The median duration of response for AlloNK + rituximab is competitive with auto-CAR-T therapies, which showed 11.1 months for Yescarta, 23.1 months for Breyanzi, and not reached for Kymriah at 40.3 months follow-up [3] Group 3: Mechanism and Future Implications - AlloNK has shown the potential to enhance the activity of monoclonal antibodies, driving deep and durable responses in both aggressive B-NHL and potentially in autoimmune diseases [2][7] - The tolerability profile of AlloNK supports its use in outpatient community settings, making it a viable option for patients with refractory autoimmune diseases [7]

IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren’s disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clini ...

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for ...

Core Insights - Affimed N.V. announced that an abstract on the phase 2 LuminICE-203 study of its innate cell engager (ICE) acimtamig in combination with AlloNK (AB-101) has been accepted for oral presentation at the ASCO Annual Meeting scheduled for May 30 – June 3, 2025 [1] - Two abstracts on AFM24 in combination with atezolizumab for non-small cell lung cancer (NSCLC) have also been accepted for poster presentations at the same event [1] Presentation Details - The oral presentation will cover the completed dose-finding part of the phase 2 study of acimtamig in combination with AlloNK for relapsed or refractory classical Hodgkin lymphoma, scheduled for May 30, 2025 [2] - The poster presentations will include initial results from a phase 2a study of AFM24 in combination with atezolizumab for advanced/metastatic EGFR-expressing NSCLC without driver mutations and for NSCLC with EGFR kinase domain mutations, both scheduled for June 2, 2025 [2] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and aims to provide innovative therapies that enable tumor-targeted approaches to treat various hematologic and solid tumors [4]

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 11:00 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings ...